Deal Digest: Gaw Capital acquires assets in Tokyo; Indonesia's PathGen raises funds

In a statement, Gaw Capital said the deal was conducted through a partnership between its Japanese real estate vehicle, in which the Qatar Investment Authority (QIA) and another unnamed institutional investor have invested, and Alyssa Partners, a minority equity investor and asset manager focused on the market.

The 29 residential properties have an average age of less than three years, with a total gross area of approximately 30,000 square meters, and comprise 835 contemporary apartment units.

PathGen Diagnostik Teknologi (PathGen), an Indonesia-based healthcare biotechnology startup, on Friday announced that it has raised an undisclosed sum from Indonesian VC firm East Ventures and conglomerate Royal Group Indonesia.

PathGen, which specialises in molecular testing solutions for cancer and other diseases, said that the funding will be allocated towards research and development, technology advancement and market expansion.

Founded in 2020, the company seeks to democratise genomics solutions in lower and middle-income countries by providing low-cost molecular diagnostics tools for cancer and other diseases.

In 2022, it launched its molecular diagnostic kit product, BioColoMelt-Dx, which is now available in cancer hospitals in Indonesia, including Dharmais Cancer Center and Cipto Mangunkusumo Hospital.